Literature DB >> 10466911

Donepezil overdose: a tenfold dosing error.

G Shepherd1, W Klein-Schwartz, R Edwards.   

Abstract

OBJECTIVE: To report toxicity resulting from donepezil administration following a tenfold dosing error. CASE
SUMMARY: A 79-year-old white nursing home patient with a history of Alzheimer disease and hypertension was inadvertently given 50 mg of donepezil instead of her usual 5-mg dose. She presented to the emergency department with nausea, vomiting, and persistent bradycardia (HR in the 40s). Routine laboratory studies were all within normal limits. Basilar rales were noted five hours after arrival. She was treated with atropine 0.2 mg as needed for bradycardia (HR <50 beats/min); a total of 3.0 mg was administered over 18 hours. Each bolus kept her HR >60 beats/min for one-half to two hours. No further vomiting or evidence of pulmonary edema occurred after her initial episodes. She returned to baseline by day 2 (HR in the 70s) and was returned to the nursing home. DISCUSSION: Donepezil is a centrally acting, reversible cholinesterase inhibitor that is used in the treatment of Alzheimer disease. Donepezil is highly specific for neural acetylcholinesterases, preferentially binding acetylcholinesterase by greater than three orders of magnitude over butyrylcholinesterases. This specificity minimizes peripheral adverse effects at therapeutic doses. Our patient mainly experienced bradycardia and had minimal secretory effects compared with what is usually seen with nonspecific cholinesterase inhibition. Medication errors like the one that produced this overdose are a common but preventable cause of morbidity in healthcare facilities.
CONCLUSIONS: A tenfold dosing error caused donepezil toxicity. The main effect of this overdose was bradycardia, which responded to atropine therapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10466911     DOI: 10.1345/aph.18273

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  11 in total

1.  Donepezil-associated bradyarrhythmia in a patient with dementia with Lewy bodies (DLB).

Authors:  Michael H Rosenbloom; Richard Finley; Melvin M Scheinman; Mitchell D Feldman; Bruce L Miller; Gil D Rabinovici
Journal:  Alzheimer Dis Assoc Disord       Date:  2010 Apr-Jun       Impact factor: 2.703

2.  Cocaine cardiovascular effects and pharmacokinetics after treatment with the acetylcholinesterase inhibitor donepezil.

Authors:  Kenneth Grasing; Deepan Mathur; Cherilyn DeSouza; Thomas F Newton; David E Moody; Marc Sturgill
Journal:  Am J Addict       Date:  2016-07-08

3.  Complete atrioventricular block and ventricular tachyarrhythmia associated with donepezil.

Authors:  T Suleyman; P Tevfik; G Abdulkadir; S Ozlem
Journal:  Emerg Med J       Date:  2006-08       Impact factor: 2.740

4.  Cardiovascular effects and risk of syncope related to donepezil in patients with Alzheimer's disease.

Authors:  Philippe Bordier; Stephane Garrigue; Stephane Lanusse; Julien Margaine; Frederic Robert; Laurent Gencel; Alexia Lafitte
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

5.  Cholinesterase inhibitors and adverse pulmonary events in older people with chronic obstructive pulmonary disease and concomitant dementia: a population-based, cohort study.

Authors:  Anne Stephenson; Dallas P Seitz; Hadas D Fischer; Andrea Gruneir; Chaim M Bell; Andrea S Gershon; Longdi Fu; Geoff M Anderson; Peter C Austin; Paula A Rochon; Sudeep S Gill
Journal:  Drugs Aging       Date:  2012-03-01       Impact factor: 3.923

6.  Causes of syncope in patients with Alzheimer's disease treated with donepezil.

Authors:  Philippe Bordier; Stephane Lanusse; Stephane Garrigue; Charlotte Reynard; Frederic Robert; Laurent Gencel; Alexia Lafitte
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

7.  [Characteristics of urinary incontinence in the elderly].

Authors:  A Wiedemann; R Anding; R Kirschner-Hermanns
Journal:  Urologe A       Date:  2014-10       Impact factor: 0.639

8.  Donepezil, anti-Alzheimer's disease drug, prevents cardiac rupture during acute phase of myocardial infarction in mice.

Authors:  Mikihiko Arikawa; Yoshihiko Kakinuma; Takemi Handa; Fumiyasu Yamasaki; Takayuki Sato
Journal:  PLoS One       Date:  2011-07-05       Impact factor: 3.240

9.  The influence of cholinesterase inhibitor therapy for dementia on risk of cardiac pacemaker insertion: a retrospective, population-based, health administrative databases study in Ontario, Canada.

Authors:  Allen R Huang; Calum J Redpath; Carl van Walraven
Journal:  BMC Neurol       Date:  2015-04-28       Impact factor: 2.474

10.  Cholinesterase inhibitors and hospitalization for bradycardia: a population-based study.

Authors:  Laura Y Park-Wyllie; Muhammad M Mamdani; Ping Li; Sudeep S Gill; Andreas Laupacis; David N Juurlink
Journal:  PLoS Med       Date:  2009-09-29       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.